Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
90 participants
INTERVENTIONAL
2019-11-04
2023-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fecal Transplant for MDR Pathogen Decolonization
NCT02906774
FMT for MDRO Colonization After Infection in Renal Transplant Recipients
NCT02922816
FMT for MDRO Colonization in Solid Organ Transplant
NCT02816437
Efficacy and Safety of FMT for the Decolonization of MDROs in the Intestinal Tract
NCT06001333
Fecal Microbiota Transplantation as a Strategy to Eradicate Resistant Organisms
NCT02543866
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Fecal microbiota transplantation
Fecal Microbiota Transplantation (FMT)
FMT using retention enema
Fecal microbiota transplantation with antibiotic pre-treatment
Fecal Microbiota Transplantation (FMT)
FMT using retention enema
No intervention follow-up
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fecal Microbiota Transplantation (FMT)
FMT using retention enema
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to provide informed consent
* Positive for one of the target MDRO by rectal or stool culture tests
* Able to provide informed consent
* Able to complete donor screening
* Able to adhere to FMT stool collection and testing procedures
Exclusion Criteria
* Pregnant or planning to become pregnant
* Breastfeeding
* Participating in another interventional or investigational study
* Neutropenic (ANC \< 0.5)
* Presence of colostomy or ileostomy
* Has an active intestinal infection
* Fever \> 38.0 or white blood count (WBC) count \> 15,000
* Are taking a non-dietary probiotic supplement
* Require or are expected to require systemic antimicrobial therapy other than Pneumocystis prophylaxis or cytomegalovirus (CMV) therapy during the study period
* Has a severe underlying disease with anticipated survival less than 6 months
* Are unable to tolerate FMT or enema for any reason, or where their physician believes for any reason that FMT might pose a health risk to the subject
* Subjects who report a history of anaphylactoid food allergy will not be excluded but these allergies will be noted and donors will be required to avoid ingestion of these foods for at least three days prior to donation
* Presence of any of the following by stool examination: vancomycin-resistant Enterococci (VRE), Salmonella, Shigella, shiga toxin-producing E. coli, Yersinia, Campylobacter, extended spectrum beta-lactamase (ESBL) producing organisms or carbapenemase-producing Enterobacteriaceae (CRE), pathogenic ova or parasites, C. difficile toxin B (by PCR), or rotavirus, adenovirus and norovirus
* History of any type of active cancer aside from melanoma
* Risk factors for acquisition of HIV, syphilis, Hepatitis B, Hepatitis C, prion or any neurological disease as determined by the donor questionnaire
* History of gastrointestinal comorbidities, e.g., inflammatory bowel disease, irritable bowel syndrome, chronic constipation or diarrhea, or colostomy or ileostomy
* Receipt of blood transfusion from a country other than Canada in the preceding 6 months
* Antibiotic use or any systemic immunosuppressive agents in the 3 months prior to stool donation
* Receipt of any live vaccine within 3 months prior to stool donation
* Any current or previous medical or psychosocial condition or behaviors which in the opinion of the investigator may pose risk to the recipients or the donor
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of British Columbia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Amee Manges
Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Providence Health Care - St. Paul's Hospital
Vancouver, British Columbia, Canada
Vancouver Coastal Health - Vancouver General Hospital
Vancouver, British Columbia, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Theodore Steiner, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H19-00782 FMT.MDRO.RCT.1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.